Balance, Aerobic Capacity, Mobility and Strength in Patients Hospitalized for Heart Failure (BAMS-HF) Program
BAMS-HF
Pilot Study of a Moderate- to High-Intensity Home-based Rehabilitation Program in Older Adults Hospitalized for Heart Failure: The Balance, Aerobic Capacity, Mobility and Strength (BAMS-HF) Program.
2 other identifiers
interventional
29
1 country
1
Brief Summary
This is a pilot randomized trial of the BAMS-HF (Balance, Aerobic capacity, Mobility and Strength in patients hospitalized for Heart Failure) Program versus usual care. The BAMS-HF Program pilot study is an initial step in eventually creating a comprehensive, patient-centered, primarily home-based rehabilitation intervention aimed at preventing worsening disability and dependence among older adults hospitalized for HF. The BAMS-HF Program will enroll patients hospitalized for HF (or with HF as an active problem during hospitalization) within the past 4 weeks and will engage patients during the vulnerable post-discharged period. The objective of this pilot study is to test the feasibility, acceptability and preliminary effect of the BAMS-HF Program in older (\>/= 65 years) adults hospitalized for HF. The BAMS-HF Program will begin within 4 week of hospital discharge and be administered 3 times weekly for 12 weeks in the patient's home upon discharge. Patients who are able to safely complete the program without in-person assistance will transition to telehealth (aka telerehabilitation) visits. The BAMS-HF Program is innovative because it is home-based, and will utilize rigorous, progressive exercises across multiple domains of physical function. The estimated preliminary effect size will be measured with the Short Physical Performance Battery (SPPB), a well-validated measure that predicts incident mobility/disability and falls in the geriatric population. Aim #1: To assess the feasibility of the BAMS-HF Program by measuring 1) study enrollment rate, 2) proportion of prescribed sessions that were actually performed, 3) proportion of patients completing full baseline assessment and outcome measures Aim #2: To assess the acceptability of the BAMS-HF Program with qualitative interviews of participants in the intervention arm that will ask about their experience in the program, any aspects of the intervention they recommend changing and whether patients would recommend the program to others. Reason for declining or stopping participation in the study will also be recorded and considered in adjusting the study protocol. Aim #3: To estimate the preliminary intervention effect by investigating the difference in change in SPPB between the BAMS-HF Program arm and the usual care arm.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable heart-failure
Started Jun 2020
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
February 17, 2020
CompletedFirst Posted
Study publicly available on registry
February 24, 2020
CompletedStudy Start
First participant enrolled
June 15, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 14, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
September 14, 2022
CompletedMarch 23, 2023
March 1, 2023
2.2 years
February 17, 2020
March 21, 2023
Conditions
Outcome Measures
Primary Outcomes (3)
Feasibility of recruiting patients into the study
Number of patients enrolled in the study each month
Monthly, up to 30 months
Acceptability of the intervention to patients randomized to the intervention arm
Qualitative interviews of participants in the intervention arm will ask about their experience in the program, any aspects of the intervention they recommend changing and whether patients would recommend the program to others. Reason for declining or stopping participation in the study will also be recorded and considered in adjusting the study protocol.
At the end of the intervention period for each patient (week 12 or at time of study dropout)
Feasibility of the protocol for patients randomized to the intervention arm
Proportion of prescribed sessions that were actually performed
At the end of the intervention period for each patient (week 12 or at time of study dropout)
Secondary Outcomes (1)
Change in Short Physical Performance Battery, which is scored from 0-16, with higher numbers indicating better functional status
At the end of 12 weeks of study enrollment for each patient
Study Arms (2)
Usual care
NO INTERVENTIONPatients in the usual care arm will receive educational material from the Heart Failure Society of America (HFSA) with the current recommendations for exercise for patients with heart failure.
BAMS-HF Program
EXPERIMENTALInterventions
BAMS-HF Program (intervention) arm will consist of 3 in-home sessions (45-60 min ea) per week for 12 weeks with the study physical therapist. The study physical therapist will transition appropriate participants to virtual in-home visits (i.e. telerehabilitation) for some visits. The study physical therapist will design individualized exercise programs first targeting strength, then mobility and balance, and finally, aerobic capacity. Exercises will be progressive, with the goal of an 8 repetition maximum for each strength component, 80% completion rate for balance/mobility components and targeting a moderate rate of perceived exertion for aerobic components. Interviews: There will be a recorded interview after the last session of the study to get participants' opinion of the program, suggestions for improvement and description of any barriers to participating in the program fully.
Eligibility Criteria
You may qualify if:
- years old or older
- Hospitalized for HF or with HF as an active problem during hospitalization
- SPPB \>/=10
You may not qualify if:
- Irreversible orthopedic or neurologic disease that severely limits mobility
- Active cancer diagnosis except non-melanoma skin cancer
- Dementia
- Life expectancy of \< 6 months
- Uncontrolled/untreated ventricular tachycardia or ventricular fibrillation
- Advanced heart failure with expectation of left ventricular assist device or transplant in the next 6 months
- Any major surgery in the past 30 days or planned in the next 10 weeks
- Discharge to a skilled nursing facility and/or home with home healthcare physical therapy (home health care nurse or occupational therapist is ok)
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Rocky Mountain Regional VA Medical Center
Aurora, Colorado, 80045, United States
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NON RANDOMIZED
- Masking
- SINGLE
- Who Masked
- OUTCOMES ASSESSOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- FED
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Staff Cardiologist
Study Record Dates
First Submitted
February 17, 2020
First Posted
February 24, 2020
Study Start
June 15, 2020
Primary Completion
September 14, 2022
Study Completion
September 14, 2022
Last Updated
March 23, 2023
Record last verified: 2023-03
Data Sharing
- IPD Sharing
- Will not share